Vascular : Acquisition May Not Be in the Best Interests of VASC Shareholders

NEW YORK, Dec. 13, 2016 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Vascular Solutions, Inc. ("VASC" or the "Company") in connection with the December 2, 2016 proposed acquisition of the Company by Teleflex Incorporated ("Teleflex"). Under the terms of the agreement, the Company's shareholders will receive $56.00 in cash for each VASC share they own.

WeissLaw is investigating whether VASC's Board acted to maximize shareholder value prior to entering into the agreement. Notably, prior to the announcement, at least one analyst set a target price of $58.00. Additionally, the deal price offers virtually no premium over VASC's December 1 closing price of $55.10. Further, the Company recently reported positive financial results, announcing that it is "proud to be completing [its] 13(th) consecutive year of double-digit percentage growth and product revenue." VASC's product-line includes more than 90 proprietary products and services that are expected to significantly accelerate Teleflex's growth in the vascular and interventional businesses. In a conference call following the announcement of the transaction, Teleflex's Chairman and CEO praised the benefits of the acquisition for Teleflex and its shareholders, namely: improvements in revenue growth, margins, earnings, and cash flow capabilities; exposure to new and faster-growing markets; and proprietorship of high growth and high margin products.

Given these facts, WeissLaw is investigating whether VASC's Board acted in the best interests of VASC's public shareholders to maximize shareholder value prior to entering into the agreement. If you own VASC shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin by telephone at [phone] or by email at [e-mail].

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [e-mail] or fill out the form on our website, http://www.weisslawllp.com/vascular-solutions-inc/

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vascular-solutions-inc-acquisition-may-not-be-in-the-best-interests-of-vasc-shareholders-300377612.html

SOURCE WeissLaw LLP